A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine

[1]  K. Secnik,et al.  Relationship of Glycemic Control to Total Diabetes-Related Costs for Managed Care Health Plan Members With Type 2 Diabetes , 2005, Journal of managed care pharmacy : JMCP.

[2]  黄亚明.  MedScape , 2009 .

[3]  G. Goodall,et al.  Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long‐term health economic implications in a Swedish setting , 2008, International journal of clinical practice.

[4]  J. Dora,et al.  Standards of Medical Care in Diabetes—2008 , 2008, Diabetes Care.

[5]  H. Janka,et al.  Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial , 2008, The European Journal of Health Economics.

[6]  S. Leichter.  Is the use of insulin analogues cost-effective? , 2008, Advances in therapy.

[7]  Krystal L. Edwards,et al.  Third‐Line Agent Selection for Patients with Type 2 Diabetes Mellitus Uncontrolled with Sulfonylureas and Metformin , 2008, Pharmacotherapy.

[8]  B. Hoogwerf,et al.  Effects of Exenatide on Diabetes, Obesity, Cardiovascular Risk Factors, and Hepatic Biomarkers in Patients with Type 2 Diabetes , 2008, Journal of diabetes science and technology.

[9]  D. Kendall,et al.  Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. , 2007, Clinical therapeutics.

[10]  H. Birnbaum,et al.  Health Care Costs of Adults Treated for Attention-Deficit/Hyperactivity Disorder Who Received Alternative Drug Therapies , 2007, Journal of Managed Care Pharmacy.

[11]  H. Birnbaum,et al.  Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data , 2007, Current medical research and opinion.

[12]  A. Maggs.  Emerging Therapies for Type 2 Diabetes , 2007 .

[13]  Donald R. Miller,et al.  Health care resource utilization and expenditures associated with the use of insulin glargine. , 2007, Clinical therapeutics.

[14]  K. Boye,et al.  Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes , 2007, Current medical research and opinion.

[15]  P. Raskin,et al.  Insulin therapy in type 2 diabetes patients failing oral agents: cost‐effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US * , 2007, Diabetes, obesity & metabolism.

[16]  G. Bray,et al.  Epidemiology, trends, and morbidities of obesity and the metabolic syndrome , 2006, Endocrine.

[17]  K. Secnik,et al.  The association between diabetes related medical costs and glycemic control: A retrospective analysis , 2006, Cost effectiveness and resource allocation : C/E.

[18]  A. Palmer,et al.  Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting , 2005, Current medical research and opinion.

[19]  R. Heine,et al.  Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes , 2005, Annals of Internal Medicine.

[20]  M. Roden,et al.  Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus , 2005, Wiener klinische Wochenschrift.

[21]  Dennis D. Kim,et al.  Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[22]  P Wainwright,et al.  Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations. , 2004, Health technology assessment.

[23]  C. Beverley,et al.  Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. , 2004, Health technology assessment.

[24]  I. Dedov,et al.  PDB11 PHARMACOECONOMIC ASPECTS OF USE OF INSULIN GLARGINE IN TREATMENT OF DIABETES MELLITUS TYPE 2 (DM T2) IN RUSSIA , 2004 .

[25]  Dennis D. Kim,et al.  Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. , 2004, Diabetes.

[26]  J. Gerich.  Insulin glargine: long-acting basal insulin analog for improved metabolic control , 2004, Current medical research and opinion.

[27]  F. Pi‐Sunyer,et al.  Obesity and type 2 diabetes. , 2003, Endocrinology and metabolism clinics of North America.

[28]  E. Finkelstein,et al.  Prevalence and costs of major depression among elderly claimants with diabetes. , 2003, Diabetes care.

[29]  J. Holst,et al.  Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. , 2002, The Journal of clinical endocrinology and metabolism.

[30]  M. Thun,et al.  Intentional Weight Loss and Mortality among Overweight Individuals with Diabetes O R I G I N a L a R T I C L E , 2022 .

[31]  D Y Lin,et al.  Methods for analyzing health care utilization and costs. , 1999, Annual review of public health.

[32]  B J McNeil,et al.  Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. , 1994, The New England journal of medicine.

[33]  C. Tilquin,et al.  Risk Adjustment in Outcome Assessment: the Charlson Comorbidity Index , 1993, Methods of Information in Medicine.

[34]  N. Duan.  Smearing Estimate: A Nonparametric Retransformation Method , 1983 .

[35]  C. Morris,et al.  A Comparison of Alternative Models for the Demand for Medical Care , 1983 .

[36]  K. Boye,et al.  Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting , 2008 .

[37]  Risto S. Cvetković,et al.  Exenatide , 2012, Drugs.

[38]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.